Key Takeaways
- Vor Bio granted stock options and RSUs to 8 newly hired employees, totaling 215,700 shares and 46,235 shares, respectively.
- The stock options have a ten-year term with exercise prices between $7.95 and $24.11, vesting over four years.
- Vor Bio is focused on advancing its novel treatment for autoimmune diseases through clinical development.
Stock Options and RSUs Granted to New Employees
Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company specializing in treatments for autoimmune diseases, announced two grant dates—November 2025 and March 23, 2026—during which their Compensation Committee awarded stock options and restricted stock units (RSUs) to 8 newly hired employees. In total, the grants include options for 215,700 shares of common stock and RSUs for 46,235 shares. These grants serve as key incentives for employment, in compliance with Nasdaq Listing Rule 5635(c)(4), and were issued under the company’s 2023 Inducement Plan.
The stock options have a tenure of ten years with exercise prices that correspond to the closing stock price on each grant date, ranging from $7.95 to $24.11 per share. The options will vest over a period of four years, with an initial 25% vesting after the first year, followed by monthly vesting of the remaining shares over the next three years, contingent upon the employees’ continued employment.
Similarly, the RSUs will also vest over a four-year timeframe, adhering to the same schedule: 25% after the first year and quarterly vesting thereafter, again dependent on continued employment.
About Vor Bio
Vor Bio aims to revolutionize the treatment of autoimmune diseases. The company is actively advancing telitacicept, a groundbreaking dual-target fusion protein, into Phase 3 clinical trials, with the goal of addressing serious autoantibody-driven conditions globally. For additional information, visit [Vor Bio’s website](http://www.vorbio.com).
The content above is a summary. For more details, see the source article.